ÂÜÀòÂÒÂ×

Clynn Wilker has a wealth of experience in the pharmaceutical industry, starting with their role as a Senior Director at NPS Pharmaceuticals from 2002 to 2007. They then moved on to become the Senior Director of Preclinical Safety Assessment at Metabasis Therapeutics, Inc from 2007 to 2009. Wilker then joined Ardea Biosciences, first as an Executive Director of Toxicology from 2009 to 2016, where they played a key role in the successful submission and approval of Zurampic. They continued their career at Heron Therapeutics, Inc. as the Vice President of Translational Sciences from 2016 to 2022. In their most recent role at Sage Therapeutics, they served as the Senior Director of Toxicology from late 2022 until their retirement in May 2023.Overall, Wilker's extensive experience in toxicology and preclinical safety assessment has made them a valuable asset to various pharmaceutical companies throughout their career.

Clynn Wilker has an extensive education history. In 1984, they graduated from Washington State University with a Bachelor of Science (BS) and a Doctor of Veterinary Medicine (DVM) degree in Veterinary Medicine, which they completed in 1998. In the years following their undergraduate studies, Clynn pursued further education in the field of animal sciences at the University of Idaho, where they obtained a Bachelor of Science (BS) degree. Additionally, Clynn engaged in a Theriogenology Residency Program at Cornell University from 1990 to 1992. Later, they attended Texas A&M University from 1992 to 1996, earning a PhD in Toxicology. Although there are references to additional education at Washington State University, Cornell University College of Veterinary Medicine, and the University of Idaho, the specific details regarding degrees and field of study are unknown.